MEMBERS Trust Co bought a new position in shares of Johnson & Johnson (NYSE:JNJ) during the first quarter, according to its most recent filing with the SEC. The firm bought 12,606 shares of the company’s stock, valued at approximately $1,570,000. Johnson & Johnson comprises about 0.1% of MEMBERS Trust Co’s investment portfolio, making the stock its 21st largest position.

Other hedge funds have also bought and sold shares of the company. Cpcm LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $1,778,000. Baillie Gifford & Co. boosted its stake in Johnson & Johnson by 2.7% in the fourth quarter. Baillie Gifford & Co. now owns 236,626 shares of the company’s stock worth $27,261,000 after buying an additional 6,110 shares during the period. Bristol Advisors LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $1,371,000. InterOcean Capital LLC boosted its stake in Johnson & Johnson by 7.0% in the fourth quarter. InterOcean Capital LLC now owns 125,123 shares of the company’s stock worth $14,415,000 after buying an additional 8,150 shares during the period. Finally, Parallel Advisors LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $2,685,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.01% during midday trading on Friday, reaching $133.10. 4,270,571 shares of the company’s stock traded hands. The stock has a market cap of $357.24 billion, a price-to-earnings ratio of 22.52 and a beta of 0.78. The stock has a 50 day moving average of $133.09 and a 200-day moving average of $126.30. Johnson & Johnson has a 52-week low of $109.32 and a 52-week high of $137.08.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same quarter last year, the business earned $1.74 earnings per share. Johnson & Johnson’s revenue was up 1.9% on a year-over-year basis. On average, equities research analysts expect that Johnson & Johnson will post $7.18 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is currently 56.76%.

WARNING: “MEMBERS Trust Co Takes Position in Johnson & Johnson (NYSE:JNJ)” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/members-trust-co-takes-position-in-johnson-johnson-nysejnj/1479104.html.

JNJ has been the subject of a number of analyst reports. Barclays PLC reiterated an “equal weight” rating and issued a $130.00 target price (up from $125.00) on shares of Johnson & Johnson in a research note on Monday, April 17th. BTIG Research reiterated a “hold” rating on shares of Johnson & Johnson in a research note on Wednesday, April 19th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $128.54 target price for the company in a research note on Monday, April 24th. Jefferies Group LLC reiterated a “hold” rating and issued a $135.00 target price (down from $140.00) on shares of Johnson & Johnson in a research note on Sunday, May 14th. Finally, J P Morgan Chase & Co upgraded shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $123.64 to $140.00 in a research note on Monday, May 15th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $133.72.

In related news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.